Get the Stockscreener App
3.63
3.71%
0.13
Pre-market:
3.54
-0.09
-2.48%
Voyager Therapeutics Inc stock is traded at $3.63, with a volume of 329.34K.
It is up +3.71% in the last 24 hours and down -3.59% over the past month.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
See More
Previous Close:
$3.50
Open:
$3.55
24h Volume:
329.34K
Relative Volume:
0.56
Market Cap:
$219.33M
Revenue:
$40.37M
Net Income/Loss:
$-119.72M
P/E Ratio:
-1.7792
EPS:
-2.0402
Net Cash Flow:
$-135.06M
1W Performance:
+7.72%
1M Performance:
-3.59%
6M Performance:
-16.74%
1Y Performance:
+10.00%
1-Day Range:
$3.504
$3.685
1-Week Range:
$3.26
$3.685
52-Week Range:
$2.83
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.63 | 219.33M | 40.37M | -119.72M | -135.06M | -2.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference - markets.businessinsider.com
Voyager Therapeutics (VYGR) director awarded 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics (VYGR) grants director 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics director granted 30,000 options | VYGR Insider Trading - Stock Titan
Voyager director granted options for 30,000 shares | VYGR Insider Trading - Stock Titan
Voyager Therapeutics (VYGR) director receives 30,000 stock options grant - Stock Titan
Voyager Therapeutics (VYGR) director granted 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics (VYGR) grants director Glenn Pierce 30,000 stock options - Stock Titan
Voyager Therapeutics Expands Authorized Shares After Stockholder Vote - TipRanks
Voyager Therapeutics (NASDAQ: VYGR) doubles authorized common stock after 2026 vote - Stock Titan
Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation - Yahoo Finance
Guggenheim Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Voyager’s tau-targeted gene therapy VY-1706 gains IND approval - BioWorld News
Voyager gets FDA clearance for Alzheimer’s gene therapy trial By Investing.com - Investing.com India
Voyager Therapeutics (VYGR) Gains FDA Approval for Alzheimer's G - GuruFocus
Voyager Therapeutics Receives FDA Clearance to Begin Clinical Trial of VY1706 Gene Therapy for Alzheimer’s Disease - Minichart
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease - markets.businessinsider.com
Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy - TipRanks
Voyager Therapeutics receives FDA clearance to begin Alzheimer’s gene therapy trial - Investing.com India
FDA clears Voyager Therapeutics (VYGR) IND for Alzheimer’s gene therapy VY1706 - Stock Titan
Voyager Receives FDA IND Clearance for VY1706, First Gene - GlobeNewswire
Voyager Therapeutics Stock Is Waking Up Before a Make-or-Break Tau Window - Bez Kabli
H.C. Wainwright Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
H.C. Wainwright reiterates Voyager Therapeutics stock rating on pipeline progress - Investing.com Australia
H.C. Wainwright reiterates Voyager Therapeutics stock rating on pipeline progress By Investing.com - Investing.com South Africa
Voyager Therapeutics Q1 2026 Earnings: Narrower‑than‑Expected Loss Drives Positive Stock Reaction - The Legal Advocate
Voyager Therapeutics Inc. (VYGR) Q1 2026 Earnings: Narrowed Loss Meets Optimism in Gene Therapy PipelineEPS Consistency Score - Newser
Voyager Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponseNet Income Trends - Newser
Voyager Therapeutics (VYGR) Shares Rebound 4.76% as Biotech Sector Shows StrengthCrowd Risk Alerts - Newser
- Insider Monkey
What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs - Insider Monkey
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Voyager Therapeutics (VYGR) accounting officer reports initial share and option holdings - Stock Titan
The one question every Voyager Therapeutics VYGR investor should ask Bullish Sentiment 20260510Weak Earnings Momentum - The Legal Advocate
VYGR (NASDAQ: VYGR) affiliate files Form 144 to sell 25,000 shares - Stock Titan
EcoR1 and Oleg Nodelman report 0 shares in Voyager (NASDAQ: VYGR) amendment - Stock Titan
Armistice Capital (VYGR) reports 3.5M shares, 5.87% stake in Voyager - Stock Titan
Voyager Therapeutics (NASDAQ: VYGR) affiliate files to sell 9,406 shares - Stock Titan
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
TradingKey - TradingKey
VYGR Technical Analysis | Trend, Signals & Chart Patterns | VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) - ChartMill
Voyager presents preclinical data for Alzheimer’s gene therapy By Investing.com - Investing.com India
Voyager Therapeutics (VYGR) Reports Positive Findings for Alzhei - GuruFocus
VYGR Secures Mission Management Contract for ISS Research - GuruFocus
Voyager presents preclinical data for Alzheimer’s gene therapy - Investing.com UK
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026 - The Manila Times
Voyager Therapeutics Advances VY1706 Gene Therapy for Alzheimer's Disease with IND Application on Track for Q2 2026 - Quiver Quantitative
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):